Q2058 Obecbtge autol up to 400 mil
Q-Codes
Also known as: Pelsmaplimab, obecabtagene autoleucel, CAR-T
Obecabtagene autoleucel CAR-T cell immunotherapy up to 400 million cells for CD19-positive hematologic malignancies.
Clinical Context
Next-generation CAR-T therapy for CD19+ hematologic malignancies with up to 400 million cell dose for enhanced efficacy.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.